Search results for " drug utilization"

showing 3 items of 3 documents

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir i…

2013

Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, define…

CyclopropanesTime FactorsPyridinesPyridineDrug ResistanceLopinavir/ritonavirLongitudinal StudieHIV InfectionsPharmacologyAntiviral therapyDeoxycytidineLopinavirCohort Studieschemistry.chemical_compoundimmune system diseasesRetrospective StudieOrganophosphonateMedicineEmtricitabineHIV InfectionPharmacology (medical)ViralLongitudinal StudiesProspective StudiesProspective cohort studyvirus diseasesLopinavirInfectious DiseasesAnti-Retroviral AgentsItalyAlkynesCombinationOligopeptideHIV/AIDSDrug Therapy CombinationOligopeptidesmedicine.drugHumanMicrobiology (medical)Benzoxazinemedicine.medical_specialtyEfavirenzTime Factorantiretroviral therapyAtazanavir SulfateOrganophosphonatesfirst-line therapy tenofovir emtricitabine atazanavir/ritonavirSettore MED/17 - MALATTIE INFETTIVEEmtricitabineDurabilityDrug TherapyInternal medicineDrug Resistance ViralDrug utilizationHumansAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Time Factors; Pharmacology; Pharmacology (medical); Infectious DiseasesTenofovirRetrospective StudiesAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time FactorsPharmacologyRitonavirbusiness.industryAdenineAtazanavirBenzoxazinesRegimenProspective StudiechemistryHIV-1RitonavirAnti-Retroviral AgentCohort StudieTenofovir/emtricitabinebusiness
researchProduct

Antimicrobial consumption and antimicrobial resistance: A snapshot of an Italian neuromuscular rehabilitation center

2017

The paper presents a snapshot of the incidence of antimicrobial-resistant microorganisms and antimicrobial consumption in an Italian rehabilitation center over a two-year period (2014-2015). Data on microorganism identification and antimicrobial susceptibility testing were obtained from the diagnostic laboratory of the hospital. A set of indicators was assessed, including the incidence density of resistant isolates per 1000 patient-days (IDRI). Data on antimicrobial consumption, semi-annually, obtained from the hospital pharmacy, were expressed as Defined Daily Dose (DDD) per 1000 patient-days. The most frequently isolated microorganism was Klebsiella pneumoniae (19.3%), and a significant i…

Microbiology (medical)GastrointestinalCathetersBacteriaSettore MED/17 - Malattie InfettiveAntimicrobial consumption; Antimicrobial resistance; DDD per 1000 patient-days; Healthcare-associated infections; Rehabilitation hospital; Anti-Bacterial Agents; Bacteria; Catheters; Drug Utilization; Intubation Gastrointestinal; Italy; Neuromuscular Diseases; Risk Factors; Drug Resistance Bacterial; Rehabilitation CentersHealthcare-Associated infections.Drug ResistanceBacterialNeuromuscular DiseasesHealthcare-associated infectionsAntimicrobial resistanceRehabilitation hospitalDDD per 1000 patient-daysRehabilitation CentersDrug UtilizationAnti-Bacterial AgentsItalyRisk FactorsAntimicrobial consumptionDrug Resistance BacterialIntubationIntubation GastrointestinalAntimicrobial consumption; Antimicrobial resistance; DDD per 1000 patient-days; Healthcare-Associated infections.; Rehabilitation hospital; Microbiology (medical)DDD per 1000 patient-day
researchProduct

The use of low molecular weight heparin in a Sicilian teaching hospital

2013

LMWH are replacing unfractionated heparin (UFH) for therapeutic anticoagulation owing to their more predictable pharmacokinetics and ease of use. Especially in Sicily, their prescription volume is steadily increasing in general practice, but little is known about their use in the hospital setting. We investigated LMWH use at the Policlinico Universitario P. Giaccone of Palermo by examining the records of drug dispensation to the wards in the years 2010-2012. From 2010 to 2012 the use of LMWH at Policlinico of Palermo remained stable with a mean of 71 DDD/100 bed days (range 69-73) of drugs dispensed. Enoxaparin, nadroparin and reviparin were the most prescribed molecules, accounting each on…

Settore BIO/14 - FarmacologiaLMWH drug utilization hospital DDD
researchProduct